Circulating levels and ex vivo production of β-chemokines, interferon γ, and interleukin 2 in advanced human immunodeficiency virus type 1 infection: The effect of protease inhibitor therapy

AIDS Research and Human Retroviruses

Volumn 16, Issue 9, 2000, Pages 835-843

  De Luca, Andrea ^a,b   Giancola, Maria Letizia ^a,b   Cingolani, Antonella ^a,b   Ammassari, Adriana ^a,b   Murri, Rita ^a,b   Antinori, Andrea ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 2; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PROTEINASE INHIBITOR; RANTES;

ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNOSTIMULATION; LYMPHOCYTE COUNT; NONHUMAN; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REPLICATION;

CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CHEMOKINES, CC; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; INTERFERON TYPE II; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; MACROPHAGE INFLAMMATORY PROTEIN-1; RANTES; RITONAVIR; RNA, VIRAL;

EID: 0034631477     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/08892220050042774     Document Type: Article

References (34)

1. 1. Clerici M and Shearer GM: A Th1-Th2 switch is a critical step in the etiology of infection. Immunol Today 1993;14:107-111.
2. 2. Fan J, Bass HZ, and Fahey JL: Elevated IFN-γ and decreased IL-2 gene expression are associated with HIV infection. J Immunol 1993;151:5031-5040.
3. 3. Graziosi C, Pantaleo G, Gnatt KR, et al: Lack of evidence for the dichotomy of Th1 and Th2 predominance in HIV-1 infected individuals. Science 1994;265:248-252.
4. 4. Barcellini W, Rizzardi GP, Borghi MO, Fain C, Lazzarin A, and Meroni PL: TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients. AIDS 1994; 8:757-762.
5. 5. Maggi E, Mezzetti M, Ravina A, et al.: Ability of HIV to promote a Th1 to Th0 shift and to replicate preferentially in Th2 and Th0 cells. Science 1994;265:244.
6. 6. Fakoya A, Matear PM, Filley E, et al.: HIV infection alters the production of both type 1 and 2 cytokines but does not induce a polarized type 1 or 2 state. AIDS 1997;11:1445-1452.
7. 7. Ward SG, Bacon K, and Westwick J: Chemokines and T lymphocytes: More than an attraction. Immunity 1998;9:1-11.
8. 8. Luster AD: Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-445.
9. 9. Virelizier J-L: Alternative, cytokine-mediated host defense mechanisms against HIV infection: The concept of self-limitation of HIV replication. AIDS 1998;12(Suppl. A):S141-S146.
10. + T cells. Science 1995;270: 1462-1466.
11. 11. Schuitemaker H, Koot M, Kootstra NA, et al.: Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992;66:1354-1360.
12. 12. Connor RI, Sheridan KE, Ceradini D, Choe S, and Landau NR: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;186:1793-1798.
13. 13. Xiao L, Rudolph DL, Owen SM, Spira TJ, and Lal RB: Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression. AIDS 1998;12: F137-F143.
14. 14. Zanussi S, D'Andrea M, Simonelli C, Tirelli U, and De Paoli P: Serum levels of RANTES and MIP-1α in HIV-positive long term survivors and progressor patients. AIDS 1996;10:1431-1432.
15. 15. Krowka JF, Gesner ML, Ascher MS, and Sheppard HW: Lack of association of chemotactic cytokines with viral burden, disease progression, or lymphocyte subsets in HIV-1 infected individuals. Clin Immunol Immunopathol 1997;85:21-27.
16. 16. Polo S, Veglia F, Malnati MS, et at.: Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection. AIDS 1999; 13:447-454.
17. 17. Palella FJ, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
18. 18. Clerici M, Hakim FT, Venzon DJ, et al: Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest 1993;91:759-765.
19. + T cells in HIV-1 infected individuals. Intervirology 1997;40:263-270.
20. + T cell levels: Results of 6 years of follow-up. J Acquir Immune Defic Syndr 1993;6:904-912.
21. 21. Andersson J, Fehniger TE, Patterson BK, et al.: Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS 1998;12:F123-F129.
22. 22. Weiss L, Si-Mohamed A, Girao P, et al.: Plasma levels of monocyte chemotactic protein-1 but not those of macrophage inhibitory protein 1-α and RANTES correlate with virus load in human immunodeficiency virus infection. J Infect Dis 1997;176:1621-1624.
23. 23. Kakkanaiah VN, Ojo-Amaize EA, and Peter JB: Concentrations of circulating beta-chemokines do not correlate with viral load in human immunodeficiency virus-infected individuals. Clin Diagn Lab Immunol 1998;5:499-502.
24. 24. Giorgi JV, Hultin LE, McKeating JA, et al.: Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999;179:859-870.
25. 25. Gougeon ML and Montagnier L: Programmed cell death as a mechanism of CD4 and CD8 T cell depletion in AIDS. Molecular control and effect of highly active antiretroviral therapy. Ann NY Acad Sci 1999;887:199-212.
26. + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-116.
27. + T cell population with memory rather than naive cells. Antiviral Res 1998;39:163-173.
28. + T cell subsets in response to highly active anti-retroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience. AIDS Res Hum Retroviruses 1998;14:561-569.
29. 29. Martinon F, Michelet C, Peguillet I, et al.: Persistent alterations in T-cell repertoire, cytokine and chemokine receptor gene expression after 1 year of highly active antiretroviral therapy. AIDS 1999;13:185-194.
30. +) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999;103:1391-1398.
31. 31. Bisset LR, Rothen M, Joller-Jemelka HI, Dubs RW, Grob PJ, and Opravil M: Change in circulating levels of the chemokines macrophage inflammatory protein 1α and 1β, RANTES, monocyte chemotactic protein 1 and interleukin 16 following treatment of severely immunodeficient HIV-infected individuals with indinavir. AIDS 1997;11:485-491.
32. 32. Aukrust P, Muller F, and Froland SS: Circulating levels of RANTES in human immunodeficiency virus type-1 infection: effect of potent antiretroviral therapy. J Infect Dis 1998;177:1091-1096.
33. 33. Kumar D, Parato K, Kumar A, Sun E, Cameron DW, and Angel JB: Sustained suppression of plasma HIV RNA is associated with an increase in the production of mitogen-induced MIP-1α and MIP-1β. AIDS Res Hum Retroviruses 1999;15:1073-1077.
34. 34. Arno A, Ruiz L, Juan M, et al.: Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤250/μL CD4 T cells and undetectable plasma virus load. J Infect Dis 1999;180:56-60.